Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
The Oncologist|August 9, 2023
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399Ryan D Gentzler, Liza C Villaruz, John C Rhee, et al.Biorxiv : the Preprint Server for Biology|July 9, 2024
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancerRemziye E Wessel, Nardin Ageeb, Joseph M Obeid, et al.Journal for Immunotherapy of Cancer|September 19, 2024
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancerRemziye E Wessel, Nardin Ageeb, Joseph M Obeid, et al.Frontiers in Oncology|January 25, 2021
MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung AdenocarcinomaBenjamin B Morris, Nolan A Wages, Patrick A Grant, et al.JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.British Journal of Haematology|March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphomaRyan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2020
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLCMark M Awad, Shirish M Gadgeel, Hossein Borghaei, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung CancerHossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.Pageof 5